TY - JOUR
T1 - Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy
AU - Aarnoutse, R.
AU - Ziemons, J.
AU - Hillege, L.E.
AU - de Vos-Geelen, J.
AU - de Boer, M.
AU - Bisschop, S.M.P.
AU - Vriens, B.E.P.J.
AU - Vincent, J.
AU - van de Wouw, A.J.
AU - Le, G.N.
AU - Venema, K.
AU - Rensen, S.S.
AU - Penders, J.
AU - Smidt, M.L.
N1 - Funding Information:
We thank the patients who participated in this study. Medical oncologists and research nurses from Catharina Hospital, VieCuri Medical Centre, Elkerliek Hospital and Maastricht University Medical Centre+ assisted with patient inclusion and sample collection. Especially, we are grateful to Marjan Laven, Ramon Bax, Sanne Achten, Eva de Jong, Angelie van de Bosch, Ilona van Rooij - Tieleman, Wendy Heuts. Monique Vercoulen, Minie Rutten and Lida Tilet. We wish to acknowledge Christel Driessen and Wesley Nix for their support in the laboratory analyses. We also thank Renée Granzier for providing support for data analysis. Finally, we would like to make a special acknowledgement to David Barnett. We are grateful for both his support in data analysis and his expertise and contribution as a Native English speaker. We thank the Kootstra Talent Fellowship who partly financially supported this study.
Funding Information:
We thank the patients who participated in this study. Medical oncologists and research nurses from Catharina Hospital, VieCuri Medical Centre, Elkerliek Hospital and Maastricht University Medical Centre+ assisted with patient inclusion and sample collection. Especially, we are grateful to Marjan Laven, Ramon Bax, Sanne Achten, Eva de Jong, Angelie van de Bosch, Ilona van Rooij - Tieleman, Wendy Heuts. Monique Vercoulen, Minie Rutten and Lida Tilet. We wish to acknowledge Christel Driessen and Wesley Nix for their support in the laboratory analyses. We also thank Renée Granzier for providing support for data analysis. Finally, we would like to make a special acknowledgement to David Barnett. We are grateful for both his support in data analysis and his expertise and contribution as a Native English speaker. We thank the Kootstra Talent Fellowship who partly financially supported this study.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/7/29
Y1 - 2022/7/29
N2 - This clinical study explored the associations between the intestinal microbiota, chemotherapy toxicity, and treatment response in postmenopausal oestrogen receptor positive breast cancer patients.Oestrogen receptor positive postmenopausal breast cancer patients were prospectively enroled in a multicentre cohort study and treated with 4 cycles of (neo)adjuvant adriamycin, cyclophosphamide (AC) followed by 4 cycles of docetaxel (D). Patients collected a faecal sample and completed a questionnaire before treatment, during AC, during D, and after completing AC-D. Chemotherapy toxicity and tumour response were determined. Intestinal microbiota was analysed by amplicon sequencing of the 16 S rRNA V4 gene-region. In total, 44 patients, including 18 neoadjuvant patients, were included, and 153 faecal samples were collected before AC-D (n = 44), during AC (n = 43), during D (n = 29), and after AC-D treatment (n = 37), 28 participants provided all four samples. In the whole group, observed species richness reduced during treatment (p = 0.042). The abundance of Proteobacteria, unclassified Enterobacterales, Lactobacillus, Ruminococcaceae NK4A214 group, Marvinbryantia, Christensenellaceae R7 group, and Ruminococcaceae UCG-005 changed significantly over time. Patients with any grade diarrhoea during docetaxel treatment had a significantly lower observed species richness compared to patients without diarrhoea. In the small group neoadjuvant treated patients, pathologic response was unrelated to baseline intestinal microbiota richness, diversity and composition. While the baseline microbiota was not predictive for pathologic response in a rather small group of neoadjuvant treated patients in our study, subsequent shifts in microbial richness, as well as the abundance of specific bacterial taxa, were observed during AC-D treatment in the whole group and the neoadjuvant group.
AB - This clinical study explored the associations between the intestinal microbiota, chemotherapy toxicity, and treatment response in postmenopausal oestrogen receptor positive breast cancer patients.Oestrogen receptor positive postmenopausal breast cancer patients were prospectively enroled in a multicentre cohort study and treated with 4 cycles of (neo)adjuvant adriamycin, cyclophosphamide (AC) followed by 4 cycles of docetaxel (D). Patients collected a faecal sample and completed a questionnaire before treatment, during AC, during D, and after completing AC-D. Chemotherapy toxicity and tumour response were determined. Intestinal microbiota was analysed by amplicon sequencing of the 16 S rRNA V4 gene-region. In total, 44 patients, including 18 neoadjuvant patients, were included, and 153 faecal samples were collected before AC-D (n = 44), during AC (n = 43), during D (n = 29), and after AC-D treatment (n = 37), 28 participants provided all four samples. In the whole group, observed species richness reduced during treatment (p = 0.042). The abundance of Proteobacteria, unclassified Enterobacterales, Lactobacillus, Ruminococcaceae NK4A214 group, Marvinbryantia, Christensenellaceae R7 group, and Ruminococcaceae UCG-005 changed significantly over time. Patients with any grade diarrhoea during docetaxel treatment had a significantly lower observed species richness compared to patients without diarrhoea. In the small group neoadjuvant treated patients, pathologic response was unrelated to baseline intestinal microbiota richness, diversity and composition. While the baseline microbiota was not predictive for pathologic response in a rather small group of neoadjuvant treated patients in our study, subsequent shifts in microbial richness, as well as the abundance of specific bacterial taxa, were observed during AC-D treatment in the whole group and the neoadjuvant group.
KW - PREOPERATIVE DOXORUBICIN
KW - GUT MICROBIOTA
KW - CYCLOPHOSPHAMIDE
KW - DOCETAXEL
KW - DYSBIOSIS
KW - BACTERIA
KW - PROTOCOL
U2 - 10.1038/s41523-022-00455-5
DO - 10.1038/s41523-022-00455-5
M3 - Article
C2 - 35906259
SN - 2374-4677
VL - 8
JO - npj Breast Cancer
JF - npj Breast Cancer
IS - 1
M1 - 89
ER -